Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-01441 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Aniek E M Schouten und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht Unive…. Hauptthemen laut MEDLINE: Breast Neoplasms, Exercise Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking. METHODS A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia. Patients with mBC (N = 357) were randomly assigned to either a 9-month, twice-weekly, supervised exercise group (EG) or control group (CG). Costs of the exercise program were calculated through a bottom-up approach. Other health care resource use, productivity losses, and quality of life were collected using country-adapted, self-reported questionnaires. Analyses were conducted from a societal perspective with a time horizon of 9 months. Costs were collected and reported in 2021 Euros (€1 = $1.18 US dollars). RESULTS Compared with the CG, EG resulted in a quality-adjusted life-year (QALY) gain of 0.013 (95% CI, –0.02 to 0.05) over a 9-month period. The mean costs of the exercise program were €1,696 per patient with one-on-one supervision (scenario 1) and €609 with one-on-four supervision (scenario 2). These costs were offset by savings in health care and productivity costs, resulting in mean total cost differences of –€163 (scenario 1) and –€1,249 (scenario 2) in favor of EG. The probability of supervised exercise being cost-effective was 65% in scenario 1 and 91% in scenario 2 at a willingness-to-pay threshold of €20,000 per QALY. CONCLUSION Exercise for patients with mBC increases quality of life, decreases costs, and is likely to be cost-effective. Group-based supervision is expected to have even higher cost-savings. Our positive findings can inform reimbursement of supervised exercise interventions for patients with mBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, A Partnership Between DKFZ and University Medical Center Heidelberg, He…
- Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
- Department for Molecular and Cellular Sports Medicine, German Sport University Cologne, Cologne, Germany.
- Gipuzkoa Cancer Unit, OSID-Onkologikoa, BioGipuzkoa, Osakidetza, San Sebastian, Spain.
- Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.
ORCID-Profile: Aniek E M Schouten, Anouk E Hiensch, Evelyn M Monninkhof, Martina E Schmidt, Dorothea Clauss, Mark Trevaskis, Helene Rundqvist, Joachim Wiskemann, Jana Müller, Renske Altena, Rhodé M Bijlsma, Gabe Sonke, G Bruce Mann, Prudence A Francis, Gary Richardson, Wolfram Malter, Elsken van der Wall, Neil K Aaronson, Ander Urruticoechea, Martijn M Stuiver, Karen Steindorf, Anne M May
Zitieren
APA
Schouten, A. E. M., Hiensch, A. E., Frederix, G. W. J., Monninkhof, E. M., Schmidt, M. E., Clauss, D., Gunasekara, N., Belloso, J., Trevaskis, M., Rundqvist, H., Wiskemann, J., Müller, J., Sweegers, M. G., Fremd, C., Altena, R., Bijlsma, R. M., Sonke, G., Lahuerta, A., Mann, G. B., …, & May, A. M. (2025). Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01441
Vancouver
Schouten AEM, Hiensch AE, Frederix GWJ, Monninkhof EM, Schmidt ME, Clauss D, et al. Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01441
BibTeX
@article{Schouten2025,
author = {Schouten, Aniek E M and Hiensch, Anouk E and Frederix, Geert W J and Monninkhof, Evelyn M and Schmidt, Martina E and Clauss, Dorothea and Gunasekara, Nadira and Belloso, Jon and Trevaskis, Mark and Rundqvist, Helene and Wiskemann, Joachim and Müller, Jana and Sweegers, Maike G and Fremd, Carlo and Altena, Renske and Bijlsma, Rhodé M and Sonke, Gabe and Lahuerta, Ainhara and Mann, G Bruce and Francis, Prudence A and Richardson, Gary and Malter, Wolfram and Kufel-Grabowska, Joanna and van der Wall, Elsken and Aaronson, Neil K and Senkus, Elzbieta and Urruticoechea, Ander and Zopf, Eva M and Bloch, Wilhelm and Stuiver, Martijn M and Wengstrom, Yvonne and Steindorf, Karen and van der Meulen, Miriam P and May, Anne M},
title = {Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-01441}
}
EUVIMED